Get the Stockscreener App
4.61
5.98%
0.26
After Hours:
4.79
0.18
+3.90%
Galectin Therapeutics Inc stock is traded at $4.61, with a volume of 473.10K.
It is up +5.98% in the last 24 hours and up +54.44% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$4.35
Open:
$4.33
24h Volume:
473.10K
Relative Volume:
0.75
Market Cap:
$464.92M
Revenue:
-
Net Income/Loss:
$-26.25M
P/E Ratio:
-11.25
EPS:
-0.4099
Net Cash Flow:
$-20.05M
1W Performance:
+14.68%
1M Performance:
+54.44%
6M Performance:
+48.23%
1Y Performance:
-1.28%
1-Day Range:
$4.33
$4.72
1-Week Range:
$3.91
$4.72
52-Week Range:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.61 | 360.03M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics (NASDAQ:GALT): Can Momentum Outrun Weak Results? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics Inc. (GALT) Peer Comparison – Compare with Others - Value Research
Galectin Therapeutics Inc. (GALT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Galectin Therapeutics (NASDAQ:GALT): Is Momentum Turning Stronger? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeuti - The National Law Review
Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn
Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn
HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade
Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart
Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus
Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView
Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com
Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative
Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo
GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat
Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewir - The National Law Review
Galectin Therapeutics (GALT) Jumps 7% to $3.45: Biotech Breakout Gains MomentumLeading Diagonal - siam.in
Galectin Therapeutics (GALT) Advances 2.48% to $3.3, Holds Above Key Support LevelLiquidity Order Flow - dars.gov.et
Galectin Therapeutics (GALT) Holds Steady at $3.10 as Shares Trade Within Tight RangeDebt Free Companies - dars.gov.et
Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion - The Globe and Mail
Galectin chairman converts $105.8 million debt to equity By Investing.com - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Galectin chairman converts $105.8 million debt to equity - Investing.com
Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet - 富途牛牛
Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan
Galectin Therapeutics Director Richard E. Uihlein Converts Convertible Notes into 34.4 Million Shares - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Galectin Therapeutics (GALT) Slides 8% as Small-Cap Biotech Selling Pressure IntensifiesEarnings Miss Risk - dars.gov.et
Galectin Therapeutics (GALT) Drops 8% as Shares Approach Key Support at $2.82Spring Pattern - vinanet.vn
Galectin Therapeutics Inc. Revenue Breakdown – NASDAQ:GALT - TradingView
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Galectin Therapeutics Inc (GALT) Cash Flow - tradingkey.com
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.470|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Option Exercise |
3.04 |
16,250 |
49,400 |
16,250 |
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Sale |
5.13 |
16,250 |
83,284 |
0 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Option Exercise |
1.23 |
22,268 |
27,390 |
28,768 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Option Exercise |
1.23 |
7,732 |
9,510 |
14,232 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Sale |
5.04 |
22,268 |
112,231 |
6,500 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Sale |
5.00 |
7,732 |
38,660 |
6,500 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Option Exercise |
2.50 |
47,467 |
118,668 |
47,467 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Option Exercise |
2.37 |
4,570 |
10,814 |
2,533 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Sale |
5.04 |
47,467 |
239,234 |
0 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Sale |
5.00 |
4,570 |
22,850 |
0 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):